ストックスクリーナーアプリを入手
0.877
4.40%
0.041
Oncolytics Biotech Inc (ONCY) 最新ニュース
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium - BioSpace
Oncolytics Biotech to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers At 2025 Asco GI Symposium - Marketscreener.com
Oncology Experts Predict 2025 Will Be a Year of Breakthroughs in Treatment and Prevention - Baystreet.ca
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus - GlobeNewswire
Oncolytics Biotech Presents Promising Cancer Treatment Data - TipRanks
Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium - PR Newswire
German PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trial - MSN
Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | CG Oncology, Targovax, Transgene, Istari Oncology, Targovax, Oncolytics Biotech - The Globe and Mail
Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA - openPR
Oncolytics Biotech (TSE:ONC) Shares Down 3.4%What's Next? - MarketBeat
Oncolytics Biotech Inc. Announces Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data - Marketscreener.com
Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail
Stocks In Play: Oncolytics Biotech Inc - Barchart
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Lelezard
Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data - Barchart
Oncolytics Biotech (TSE:ONC) Trading Down 3.4%Time to Sell? - MarketBeat
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga
Investors Eye Biotech Stocks as Cancer Therapies Take Center Stage in 2025 - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Advances Pancreatic Cancer Treatment with Regulatory Approval - TipRanks
Oncolytics Biotech (TSE:ONC) Share Price Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat
Oncolytics Biotech (TSE:ONC) Shares Pass Below 200-Day Moving Average – Here’s Why - Defense World
A Data-Based Look At Oncolytics Biotech, Inc (ONCY) - Stocks Register
Oncolytics Biotech® to Host Conference Call to Discuss First Qua - GuruFocus.com
Suncor Energy Inc (SU-N) QuotePress Release - The Globe and Mail
Oncolytics Biotech (NASDAQ:ONCY) Stock Price Up 3.2% – Still a Buy? - Defense World
Oncolytics Biotech (TSE:ONC) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Trading Up 3.2%What's Next? - MarketBeat
Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely? - Yahoo Finance
Oncolytics Biotech (TSE:ONC) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
Oncolytics Biotech (TSE:ONC) Stock Passes Above 200 Day Moving Average – Here’s Why - Defense World
Oncology In Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Barchart
The Immunotherapy Boom: What It Means For The Future Of Cancer Treatment - MENAFN.COM
The Immunotherapy Boom: What It Means for the Future of Cancer Treatment - Baystreet.ca
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook - GlobeNewswire
Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data - Barchart
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options - Informazione.it
Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data – Company AnnouncementFT.com - Financial Times
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses - Lelezard
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector - Baystreet.ca
Oncolytics Biotech (TSE:ONC) Trading Up 14.5%Should You Buy? - MarketBeat
From Crisis To Opportunity: How Advances In Immunotherapy Are Shaping The Oncology Sector - MENAFN.COM
Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium - The Malaysian Reserve
Stocks In Play: Oncolytics Biotech Inc. - Barchart
Early-Onset Cancer Trends Spark Interest In Promising Oncology Pipelines - MENAFN.COM
Oncolytics Biotech Inc. - Baystreet.ca
Early-Onset Cancer Trends Spark Interest in Promising Oncology Pipelines - Baystreet.ca
1.34%
6.93%
大文字化:
|
ボリューム (24 時間):